Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

Tropic Biosciences raises $10 mln

Tropic Biosciences said June 13 that closed a $10 million Series A round led by Pontifax AgTech and Five Seasons Ventures. The round included several co-investors, including Tekfen Ventures, Emerald Technology Ventures, Bits x Bites, Midven-RSF and the family offices of Gigi Levy-Weiss and Antonio Moreira Salles. Tropic Biosciences is developing plant varieties in the tropical agriculture industry using CRISPR Gene Editing. PRESS RELEASE ropic Biosciences closes $10 million Series A funding round led by Pontifax AgTech with Five Seasons Ventures NORWICH, 13 June 2018: Tropic Biosciences, a pioneering leader in the development of new plant varieties in the massive tropical agriculture industry using CRISPR Gene Editing, is proud to announce the close of its $10 million Series A funding round. Proceeds from the round will support the commercialisation of the company’s novel non-GMO coffee and banana varieties and allow its global expansion into additional promising crop segments. Series A
Continue reading "Tropic Biosciences raises $10 mln"

Tropic Biosciences raises $10 mln

Tropic Biosciences said June 13 that closed a $10 million Series A round led by Pontifax AgTech and Five Seasons Ventures. The round included several co-investors, including Tekfen Ventures, Emerald Technology Ventures, Bits x Bites, Midven-RSF and the family offices of Gigi Levy-Weiss and Antonio Moreira Salles. Tropic Biosciences is developing plant varieties in the tropical agriculture industry using CRISPR Gene Editing. PRESS RELEASE ropic Biosciences closes $10 million Series A funding round led by Pontifax AgTech with Five Seasons Ventures NORWICH, 13 June 2018: Tropic Biosciences, a pioneering leader in the development of new plant varieties in the massive tropical agriculture industry using CRISPR Gene Editing, is proud to announce the close of its $10 million Series A funding round. Proceeds from the round will support the commercialisation of the company’s novel non-GMO coffee and banana varieties and allow its global expansion into additional promising crop segments. Series A
Continue reading "Tropic Biosciences raises $10 mln"